NCT02977468 Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer Status RECRUITING Phase PHASE1
NCT02938442 Vaccination of Triple Negative Breast Cancer Patients Status COMPLETED Phase PHASE1/PHASE2
NCT02936102 A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Status TERMINATED Phase PHASE1
NCT02807844 Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Status COMPLETED Phase PHASE1/PHASE2
NCT02802423 Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT02768701 Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer Status COMPLETED Phase PHASE2
NCT02750358 Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02734290 Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02685657 Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer Status UNKNOWN Phase PHASE2
NCT02685306 A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer Status WITHDRAWN Phase PHASE2
NCT02681562 Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients Status UNKNOWN Phase PHASE2
NCT02657889 Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT02644369 Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02641847 TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature Status ACTIVE_NOT_RECRUITING Phase PHASE2/PHASE3
NCT02639832 A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation. Status UNKNOWN Phase N/A
NCT02632448 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT02616848 Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers Status UNKNOWN Phase PHASE1
NCT02615457 Huaier Granule in Treating Women With Triple Negative Breast Cancer Status RECRUITING Phase PHASE4
NCT02595138 Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer Status UNKNOWN Phase PHASE3